Some processes have plagued the research industry for decades. They’re inefficient and unpopular, but somehow resistant to ...

While Vir Biotech is best known for its work on infectious diseases, its developing cancer pipeline has delivered a partnership with Astellas that could be worth around $1.4 billion.

Reimbursement authority NICE has said that Incyte's JAK inhibitor cream Opzelura (ruxolitinib) can be used to treat people ...

The results in a Chinese population living with obesity are the first major readout for UBT251, a 'triple G' agonist of the ...

The changes to the Quality and Outcomes Framework (QOF) incentive programme mean that GPs will be able to receive up to £3,000 per year for Mounjaro (tirzepatide) prescriptions and another £1,000 for ...

The new oncology division will be run by Jannie Oosthuizen, previously head of Merck Human Health US, while the non-oncology ...

The final piece of this evolution comes from closing the loop between AI scientists and the physical laboratory. In 2026, AI systems will connect seamlessly with robotic laboratories, creating true ...

The FDA has sketched out its new regulatory pathway to market for individualised therapies that treat ultra-rare diseases, based on a 'plausible mechanism' premise.

Gilead Sciences has shored up its position in cell therapies for cancer with a deal to acquire Arcellx, a company it has been ...

CagriSema was submitted for FDA approval last December as a treatment for obesity last December, with a decision due later ...

Among the issues highlighted by patients in the study were lengthy waits for appointments, obstacles to changing or ...

On the sidelines of JPM, Daiichi-Sankyo US CEO Ken Keller told pharmaphorum about the company's big year and its long-term s ...